Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer,Accounts of Chemical Research

当前位置： X-MOL 学术 › Acc. Chem. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer
Accounts of Chemical Research ( IF 16.4 ) Pub Date : 2022-09-19 , DOI: 10.1021/acs.accounts.2c00346
Zheng-Rong Lu _{1,

2} , Victoria Laney ₁ , Yajuan Li ₃

Affiliation

Magnetic resonance imaging (MRI) is a clinical imaging modality that provides high-resolution images of soft tissues, including cancerous lesions. Stable gadolinium(III) chelates have been used as contrast agents (CA) in MRI to enhance the contrast between the tissues of interest and surrounding tissues for accurate diagnostic imaging. Magnetic resonance molecular imaging (MRMI) of cancer requires targeted CA to specifically elucidate cancer-associated molecular processes and can provide high-resolution delineation and characterization of cancer for precision medicine. The main challenge for MRMI is the lack of sufficient sensitivity to detect the low concentration of the cellular oncogenic markers. In addition, targeted CA must satisfy regulatory safety requirements prior to clinical development. Up to now, there is no FDA-approved targeted CA for MRMI of cancer.

中文翻译：

用于癌症磁共振分子成像的靶向造影剂

磁共振成像 (MRI) 是一种临床成像模式，可提供软组织（包括癌性病变）的高分辨率图像。稳定的钆 (III) 螯合物已被用作 MRI 中的造影剂 (CA)，以增强目标组织与周围组织之间的对比度，从而实现准确的诊断成像。癌症的磁共振分子成像 (MRMI) 需要有针对性的 CA 来专门阐明与癌症相关的分子过程，并可以为精准医学提供高分辨率的癌症描绘和表征。MRMI 的主要挑战是缺乏足够的灵敏度来检测低浓度的细胞致癌标记物。此外，目标 CA 在临床开发之前必须满足监管安全要求。到现在，

更新日期：2022-09-19

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南